Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2026-02-01 @ 3:42 AM
Study NCT ID:
NCT02284568
Status:
COMPLETED
Last Update Posted:
2022-03-10
First Post:
2014-10-31
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01-12
Start Date Type:
ACTUAL
Primary Completion Date:
2017-05-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-10-01
Completion Date Type:
ACTUAL
First Submit Date:
2014-10-31
First Submit QC Date:
None
Study First Post Date:
2014-11-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-08-16
Results First Submit QC Date:
None
Results First Post Date:
2018-11-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-05-11
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-03-09
Last Update Post Date:
2022-03-10
Last Update Post Date Type:
ACTUAL